[ad_1]
The well-known development of a vaccine at the University of Oxford promises unexpectedly positive results against the coronavirus. There is more good news, one of which is that it is conceivable that British health workers could receive the vaccine that offers protection from January.
Attempts to develop a vaccine against the Oxford coronavirus hold great promise for older people, the Financial Times reports. Tests conducted over a long period of time suggest that vaccination shows great promise, especially for this age group. A drug developed jointly by the University of Oxford and the pharmaceutical factory AstraZeneca is considered the vaccine that can obtain a marketing authorization that meets Western standards as soon as possible. (A vaccine is already being used in Russia, but it was started before their tests were finished.)
The Oxford formulation shows good results, especially in older test subjects, that is, a strong immune response to coronavirus, the British business newspaper learned from two informants. This is the age group most at risk. Based on this, we can be confident that older people can avoid serious and life-threatening coronavirus disease. The researchers originally hoped that as people weaken their immune systems as they age, they will be the weakest to respond to the vaccine.
Test results
As early as the summer, research revealed that the vaccine elicited a strong immune response in test subjects between the ages of 18 and 55. Two types of responses have been observed, such as an increase in antibodies and T lymphocytes, with at least 56 days of protection, according to a study by The Lancet. Of course, this does not guarantee that the product is effective and safe for the elderly.
We can only get a glimpse of this after the tests are finally completed, but the researchers are confident in the latest scientific findings. Although the University of Oxford has not officially commented on the leaked news, Jonathan Ball, professor of virology at the University of Nottingham, believes that if the data supports the good news about the elderly, we are definitely facing encouraging developments. However, he cautioned: the most important testing phase, which many people are experimenting with, is not over yet.
Optimism
According to an insider close to the British government apparatus, both vaccine developers and back-end authorities are very optimistic. They trust that the most vulnerable groups, especially the staff of the National Health Organization (NHS), will be able to get vaccinated against the coronavirus from January. In this sense, it warns again that the third phase of testing has not yet been completed and that it is about how the formal authorization procedure will be carried out.
A few days ago Patrick Vallance, chief scientific adviser to the British government, said that vaccine research is progressing well, but that the first vaccines are not expected to be available before next spring. Testing in the US branch of the Oxford / AstraZeneca couple was recently resumed after the series of studies was halted in early September because one of the participants was showing symptoms of a serious neurological disease.
[ad_2]
